ST-elevation heart attack (STEMI)
A STEMI is a heart attack in which the ST segment of the electrocardiogram stays raised. It comes with the symptoms of reduced blood flow to the heart and with blood signs of injury to the heart muscle, such as a raised troponin level. Whether the ST segment is raised is often used to decide how the heart attack is treated. A heart attack without that raised segment is called an NSTEMI.
Also called STEMI · ST-elevation myocardial infarction · ST Elevation Myocardial Infarction
- Condition
- In this atlas
Overview
Technical summary
MeSH D000072657, last updated 2019-07-01; the definition rests on its scope note. The place under acute coronary syndrome rests on the first sentence of the abstract of one open-access paper (PMC11904130). A US government patient page on heart attack gives the general facts for the parent record; it does not mention ST elevation.
Burden
No burden claims are published.
Claims and evidence
No claims are published for this condition yet.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Evaluated for this: Clopidogrel
Applies to Recipient not specified People for whom the US label of clopidogrel (Plavix) lists an indication: acute coronary syndrome, acute ST-elevation myocardial infarction managed medically, recent myocardial infarction, recent stroke, established peripheral arterial disease
Population, setting and follow-up
- Patients described in the indications section of the label. The label passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Plavix (clopidogrel), in the Sanofi-Aventis U.S. LLC version dated 2025-05-30 in openFDA, lists the medicine to reduce the rate of myocardial infarction and stroke in patients with acute coronary syndrome without ST-segment elevation (unstable angina or non-ST-elevation myocardial infarction), in patients with acute ST-elevation myocardial infarction who are to be managed medically, and in patients with established peripheral arterial disease or a history of recent myocardial infarction or recent stroke. The label carries a boxed warning titled diminished antiplatelet effect in patients with two loss-of-function alleles of the CYP2C19 gene.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the title of the boxed warning and the mechanism sentence were read; contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Prasugrel
Applies to Recipient not specified People for whom the US label of prasugrel (Effient) lists an indication: acute coronary syndrome managed with percutaneous coronary intervention
Population, setting and follow-up
- Patients described in the indications section of the label. The label passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Effient (prasugrel), in the Cosette Pharmaceuticals, Inc. version dated 2022-09-07 in openFDA, lists the medicine to reduce the rate of thrombotic cardiovascular events, including stent thrombosis, in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI): patients with unstable angina or non-ST-elevation myocardial infarction, and patients with ST-elevation myocardial infarction managed with primary or delayed PCI. The label carries a boxed warning that the medicine can cause significant, sometimes fatal, bleeding.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the first line of the boxed warning and the mechanism sentence were read; the rest of the boxed warning, contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA's version may be older than the current label. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Tenecteplase
Applies to Adult Adults for whom the US label of tenecteplase (TNKase) lists an indication: acute ischemic stroke, acute ST-elevation myocardial infarction
Population, setting and follow-up
- Adult patients described in the indications sections of the label.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Adults, as the passages read state
The US label of TNKase (tenecteplase), in the Genentech, Inc. version dated 2025-12-15 in openFDA, describes the medicine as a tissue plasminogen activator (tPA) and lists it, in adults, for the treatment of acute ischemic stroke (AIS) and to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI).Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label has no boxed warning section in openFDA; time limits, contraindications, doses, interactions and bleeding warnings were not read. openFDA also lists a second TNKase record with only the myocardial infarction indication. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 220
Record details
- Record id
cardio:stemi- Content hash
ab640ccff7e091e5578680311f6a5adf89c588ceea8fc19970dad46f9e1a4a83